Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 51-60 of 381 for

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. Differences in Immunological Effects of Vitamin D Replacement Among African American Prostate Cancer Patients With Localized Versus Metastatic Disease

    Jacksonville, FL, Scottsdale/Phoenix, AZ

  2. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma

    Rochester, MN

  3. Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

  4. Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma

    Scottsdale/Phoenix, AZ, Rochester, MN

  5. A Study to Compare Somatostatin Analogues with Perioperative Antibiotics versus Prolonged Antibiotics

    Rochester, MN

  6. A Study of JNJ‐68284528 Out‐of‐Specification (OOS) for Commercial Release in Patients with Multiple Myeloma

    Rochester, MN

  7. A Patient Access Program of Olaratumab for the Continued Treatment of Soft Tissue Sarcoma

    Jacksonville, FL

  8. Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

    Rochester, MN

  9. A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer

    Rochester, MN

  10. Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

    Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer